0001867096-24-000016.txt : 20240131
0001867096-24-000016.hdr.sgml : 20240131
20240131170455
ACCESSION NUMBER: 0001867096-24-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240131
DATE AS OF CHANGE: 20240131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND
CENTRAL INDEX KEY: 0001743774
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 24583841
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 871082097
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
4
1
wk-form4_1706738685.xml
FORM 4
X0508
4
2024-01-31
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001743774
JOHNSON KENNETH ERLAND
C/O XERIS BIOPHARMA HOLDINGS, INC.
1375 WEST FULTON STREET, SUITE 1300
CHICAGO
IL
60607
0
1
0
0
See Remarks
0
Common Stock
2024-01-31
4
A
0
175000
0
A
446860
D
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
These shares include 2,077 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
Senior Vice President, Global Development and Medical Affairs
/s/ Beth Hecht, as Attorney-in-Fact
2024-01-31